A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495

• Status: Completed
• Trial end date: 2021-05-20
• Target enrollment: 0
• Participant gender: All

Summary

To Evaluate the Efficacy and Safety of CKD-495

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chong Kun Dang Pharmaceutical
• Treatments: Ethanol

Criteria

Inclusion Criteria:

1. Male or Female subjects aged ≥ 19

2. Acute or Chronic gastritis patients who have more than 1 erosion on endoscopy within 7days prior to the use of the Investigator's Product taken date

3. Patients who have more than 1 subjective symptom

Exclusion Criteria:

1. Patients with peptic ulcer, gastroesophageal reflux disease, malignant tumor in the digestive system or coagulation disorder, or taking antithrombotic medicine

2. Patients who have been taken any gastritis medicine that could affect the treatment:

H2 receptor antagonist, PPI(Proton Pump Inhibitor), antacid, improvement of movement in digestive system, Prostaglandin, and protective agent for gastritis

3. Patients who have to take medicine that could cause gastritis